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Abstract: Impulse control disorders (ICDs) occur in a subset of Parkinson’s disease (PD) patients on dopaminergic
medications however there are currently no reliable markers to identify patients at risk. Sleep disturbances are more common
in patients with an ICD. Serum ferritin levels have been associated with PD disease stage and progression, but have not
previously been associated with impulsivity levels. The objective of this study was to determine if serum ferritin levels and
sleep disturbance are associated with high traits of impulsivity and ICD in a cohort of PD patients attending a movement
disorders clinic. This study assessed impulsiveness in 87 PD patients using the Barratt Impulsiveness Scale. Severity of sleep
disturbance was determined using the sleep-related items of the MDS-UPDRS. Serum ferritin, iron and transferrin levels were
measured in patients, as well as 36 age-matched healthy controls. Serum ferritin levels were significantly elevated in male PD
patients in the high impulsivity group compared to patients in the low (p=.022) and normal range groups (p=.024) and showed
a linear increase across the three groups. Sleep disturbance also demonstrated a linear trend, which was most severe in the high
impulsivity group (p=.030). A subgroup of 11 male PD patients who fulfilled the DSM-5 criteria for an ICD had significantly
higher ferritin levels and more severe sleep disturbance when compared with the remaining male PD cohort. Serum ferritin
levels and sleep disturbance severity are highlighted as potential markers for abnormal impulsivity and ICD in PD patients.
Keywords: Impulsivity, BIS-11, Ferritin, Sleep Disturbance, PD

1. Introduction
Impulse control disorders (ICDs) are becoming
increasingly identified as a consequence of dopaminergic
medication in Parkinson’s disease (PD) [1]. Recent studies
suggest ICDs occur in upwards of 40% of PD patients [2],
with males more likely to report multiple impulsive
behaviours than females [3]. While there are currently no
reliable predictive markers for the development of an ICD,
patients with higher traits of impulsivity may be more

susceptible, although this is yet to be established. Patients
displaying high impulsivity traits are known to have a
younger age at PD onset [3] and are also more likely to be
individuals who have recurrent falls [4].
Sleep deprivation and disturbances are known to increase
impulsive behaviours [5]. Moreover, patients with PD
experience greater sleep-related problems [6], a feature
possibly exacerbated by medications such as dopamine
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agonists [7, 8]. Sleep disturbances, including sleep
fragmentation and daytime sleepiness, are more common in
PD patients with ICDs than PD alone and healthy controls
[9]. Similar patterns of sleep disturbance have been linked to
impulsive behaviour in other related disorders such as
Attention Deficit/Hyperactivity Disorder (ADHD) and
restless legs syndrome (RLS) [10, 11], both of which have
been associated with low serum levels of the iron storage
protein, ferritin [12, 13]. Moreover, in a study of children
with ADHD, Oner and colleagues (2012) identified a
relationship between serum ferritin and hyperactivity scores
[14], presenting a possible marker for broader impulse
control conditions.
A number of studies have shown that there is a selective
accumulation of iron in the substantia nigra in PD [15] and
changes in levels of the major iron-binding protein ferritin,
however it is unclear what role they play in the pathogenesis
of the disease [16]. Studies examining serum levels of ferritin
in PD patients have been inconclusive, showing either
increased levels [17], or no significant relationship [18, 19].
Ferritin levels have been reported to be increased in both
male and female PD patients when compared to controls,
correlating with Hoehn & Yahr stage and disease duration
[20]. However, limited studies have investigated ferritin
levels during disease progression, most importantly in the
context of non-motor aspects of the disease, and an
association between ferritin and impulsivity levels has not
previously been investigated.
Thus, the present study investigated whether trait
impulsivity was associated with sleep disturbance and serum
levels of ferritin, iron and transferrin in a cohort of PD
patients without a prior history of an ICD.

2. Methods
2.1. Subjects
Eighty-seven home-based PD patients (54 males) were
sequentially recruited from the Movement Disorders Clinic at
the Perron Institute for Neurological and Translational
Science (Perth, Australia) between 2008 and 2015. All
patients were examined by a movement disorder neurologist
prior to inclusion in the study for verification of the diagnosis
in accordance with the UK Brain Bank criteria for IPD [21].
All PD patients were taking levodopa and 49 patients were
also on a dopamine agonist (cabergoline, pramipexole,
ropinirole or rotigotine). All PD medications were converted
to levodopa equivalent daily doses (LEDD) [22]. Fourteen
patients had implanted GPi deep brain stimulators (DBS).
None of the patients had a history of liver disease or of a
chronic inflammatory or iron storage disorder. For serum
analysis, 36 age-matched healthy control samples were also
collected. This study was approved by the Sir Charles
Gairdner Hospital Human Research and Ethics Committee
(Approval number 2006/073), and written informed consent
was obtained from all participants, in accordance with the
National Health and Medical Research Council guidelines.
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2.2. Clinical Assessments and Diagnosis of Impulse Control
Disorders
All clinical assessments were evaluated in the ‘ON’ state.
Motor symptoms were evaluated using the MDS-Unified
Parkinson's Disease Rating Scale (MDS-UPDRS) Part III,
and Hoehn and Yahr Scale [23]. In addition, each participant
was evaluated by a clinical psychologist and completed a
battery of neuropsychological assessments. The ‘Barratt
Impulsivity Scale 11’ (BIS-11) was employed as a validated
self-report questionnaire for screening impulsivity [24].
During the screening process, patients displaying any signs
of an impulse control disorder were invited to seek further
consultation with the clinical psychologist. Patients attending
the subsequent consultation underwent a formal
psychological evaluation, whereby a formal diagnosis of ICD
was made based on the DSM-5 diagnostic criteria [25].
Venous blood samples were collected from patients and
controls at the time of clinical assessment. For serum analysis
of ferritin, transferrin, and iron, blood was collected from all
PD patients and healthy controls.
2.3. Determination of Sleep Problems
Patient sleep disturbance was calculated by combining
patient ‘night-time sleep problems’ (MDS-UPDRS item 1.7)
and ‘daytime sleepiness’ (MDS-UPDRS 1.8). This combined
score has previously been validated against other scales for
measuring sleep disturbances, such as the ‘Epworth
Sleepiness Scale’ and the ‘PD Sleep Scale Version 2’ (PDSS2) [26].
2.4. Statistical Methods
Data was analysed using IBM-SPSS (v. 24, IBM
Corporation). A significant nominal P-value of ≤0.05 was
employed. One-way analysis of variance (ANOVA) tests
with Tukey post-hoc analysis were used to compare the
difference between defined impulsivity groups. In addition,
the assessment for homogeneity of variance between groups
was undertaken using Levene’s test. In addition to the
ANOVA, for the assessment of covariates such as age, an
analysis of covariance (ANCOVA) was undertaken, and
described where appropriate. For gender comparisons, and
comparison between demographic variables, independent ttests or Mann-Whitney U were used.

3. Results
3.1. Demographic and Clinical Correlates of Impulsivity in
PD Patients
The PD cohort enrolled in this study has previously been
described [27], and was broadly ranging in age (68.9 ± 31.8
yrs), age of onset (53.3 ± 10.2 yrs), and disease duration
(10.4 ± 6.8 yrs) and had no prior history of an ICD. In an
effort to identify demographic and clinical indicators of
patient impulsivity, the effects of gender, smoking history,
PD medications and DBS surgery were examined and no
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significant associations were found with the total BIS-11
impulsivity scores (data not shown).
To determine if patient impulsivity was associated with
other clinical markers in PD, BIS-11 scores were grouped
into low (<52), normal (52-71) and high levels (>72) [24].
Given the previously reported link between recurrent falling
and patient impulsivity in PD, this study first examined
gender differences in disease severity, as determined by
motor examination (MDS-UPDRS III). Patients selfreporting higher traits of impulsivity displayed a worsened
disease severity, with significance only between groups in
male PD patients (p<.05). Given the established link between
impulsivity and sleep disturbance, the authors subsequently
investigated whether patients in this cohort exhibited a
similar relationship. Sleep disturbance in patients, as
measured by UPDRS 1.7 and 1.8, was significantly
associated with impulsivity groups (p<.05). Sleep
disturbance scores were significantly higher in the high
impulsivity group (p<.026), compared to patients in the
normal-range group. Moreover, this association was observed
in male, but not female patients (Figure 1B).
Table 1. Descriptive statistics of the Parkinson’s Disease cohort (n=87).
Clinical Characteristic/Assessment
Age (Years)
Age of onset (Years)
BIS-11
Disease duration (Years)
Daily LD equivalents (mg/day)
Hoehn Yahr (Stage 0-4)
MDS-UPDRS III Score

Mean (±SD)
68.9 (31.8)
53.3 (10.2)
61.8 (10.0)
10.4 (6.8)
671 (389)
1.6 (1.0)
12.8 (14.2)

LD: Levodopa; UPDRS: Unified Parkinson’s Disease Rating Scale

3.2. Impulsivity Levels Relate to Serum Ferritin and
Transferrin Saturation Levels

PD patients (n=87) when compared to healthy age-matched
controls (n=36), however this difference did not reach
statistical significant. When the effect of gender was
considered, elevated ferritin levels were observed in male PD
patients and healthy controls, when compared to females
(p<.001), but there were no significant differences between
PD patients and controls (Figure 2A). Serum ferritin levels
showed a significant main effect between impulsivity groups
(p<.05), with a significant increase in the high impulsivity
group when compared to the normal and low impulsivity
groups (p<.05). Male patients displayed a greater difference
in serum ferritin between impulsivity groups (p<.05), with an
incremental rise in the three groups (Figure 2B). In contrast,
female PD patients did not demonstrate the same significant
relationship between impulsivity groups.
In the whole cohort of PD patients, serum iron and
transferrin saturation were not significantly altered, when
compared to healthy age-matched controls (Figure 2C and
2E). When analysing the effect of gender, elevated iron levels
were observed in male patients within the high impulsivity
group (Figure 2D), but these results did not reach
significance (p=.054). Transferrin saturation (serum iron
level x 100 / total iron-binding capacity) showed no
difference in the low and normal range impulsivity groups.
However, male patients in the high impulsivity group
displayed significantly higher transferrin saturation levels
than female patients (p<.05) in the same group (Figure 2F).
To confirm these findings, ANCOVA analysis using age
and LEDD as covariates were performed. In the male cohort,
age and LEDD were not significant contributors to the
observed variance in ferritin levels. Moreover, impulsivity
(BIS-11) grouping was a significant variable (p<.05), and
pairwise comparisons of adjusted means revealed
significance between high and normal impulsivity groups
(p=.010).

Serum ferritin levels were elevated in the overall cohort of

Figure 1. Clinical assessment indicators of impulsivity scores (BIS-11). When PD patients were grouped by impulsivity scores: (A) patients in the high
impulsivity group had greater disease severity (MDS-UPDRS III), reaching statistical significance in male groups. (B) Gender-specific differences in sleep
disturbance between impulsivity groups with an incremental increase in severity of sleep disturbance in males. Data shown are the mean ± standard error;
*p<.05: **p<.005.
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A.

B.

48

*

*

***

C.

D.
p =.054

E.

F.
*

Figure 2. Serum ferritin, iron and transferrin saturation levels. (A) Ferritin levels were significantly higher in males than females both in the PD and control
groups (B) Gender-specific differences in serum ferritin levels between impulsivity groups with an incremental rise in male PD patients but not females. (C)
Serum iron levels were not significantly altered between control subjects compared with PD patients, or (D) between impulsivity groups. (E) Transferrin
saturation percentage was not significantly altered between control subjects compared with PD patients. (F) Within the high range impulsivity group,
transferrin saturation percentage was elevated in males but not females. Data shown are the mean ± standard error; *p<.05, **p<.005, ***p<.001.

3.3. Subset of Patients Diagnosed with an ICD
Following the preliminary psychological assessment and administration of the BIS-11, 11 patients (all males) with the
highest impulsivity scores volunteered to undergo a more detailed evaluation by a clinical psychologist and were all found to
meet the DSM-5 criteria for the diagnosis of an ICD. Their demographic and clinical features are detailed in Table 2 in
comparison to the other 43 males in the PD cohort.
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Table 2. Baseline Clinical Characteristics of the male PD (n=43), and diagnosed ICD patient subset (n=11).
Clinical Characteristic/Assessment
Age (Years)
Age of onset (Years)
Disease duration (Years)
Daily LD equivalents (mg/day)
Hoehn Yahr (Stage 0-4)
UPDRS III Score

Male PD patients Mean (± SD)
62.95 (11.1)
52.98 (12.0)
11.05 (7.6)
755.5 (424.6)
1.67 (0.9)
18.30 (13.81)

ICD subset Mean (± SD)
63.55 (7.4)
52.64 (8.3)
11.73 (6.2)
590.9 (375.3)
1.73 (1.1)
24.09 (14.73)

LD: Levodopa; UPDRS: Unified Parkinson’s Disease Rating Scale

A.

B.

*

C.

D.
*

*

E.
*

Figure 3. Comparative assessments of serum markers in ICD, male PD and male healthy controls. (A) Ferritin levels were significantly higher in ICD males
compared to PD males, but not healthy controls (B) Serum iron levels were not significantly different between groups. (C) Transferrin levels were significantly
reduced in the ICD group when compared with healthy control males. (D) Transferrin saturation was significantly elevated in the ICD cohort, when compared
to males in the control and PD groups. (E) Patient sleep disturbance was significantly greater in males with an ICD compared with the male PD patients.
Data shown are the mean ± standard error; *p<.05.
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3.4. Male ICD Patients show Higher Serum Ferritin Levels
and Greater Sleep Disturbance
To determine if findings relating to serum ferritin, iron,
and transferrin saturation were also observed between
groups, serum levels were compared between the subset of
ICD patients, other male PD patients, and healthy male
controls (Figure 3). Significantly higher ferritin levels and
transferrin saturation, and significantly lower transferrin
levels were observed in the ICD group when compared to the
other male PD patients and healthy control males (p<.05).
Serum iron levels were significantly higher than in the other
PD males, but not male healthy controls. Similarly, selfreported sleep disturbance (UPDRS 1.7 and 1.8) was greater
in the ICD subset, when compared to the other PD male
group (p=.038).

4. Discussion
Findings from the present study demonstrated that when
impulsivity scores were stratified into low, normal and high
levels, male patients in the high impulsivity group had
significantly greater motor impairment, as shown by higher
UPDRS III scores, than males in the normal or low
impulsivity groups. Interestingly, despite a similar trend with
female patients, no significant differences in UPDRS III
scores were observed between impulsivity groups. Similarly,
the authors also observed a gender specific difference in the
severity of sleep disturbance, with males in the high
impulsivity group reporting greater disturbances then
females. In addition, an incremental increase in sleep
disturbance severity was observed in males across the three
impulsivity groups. The basis for the association between
sleep disturbance and impulsiveness is uncertain, specifically
whether sleep disturbance increases impulsivity and the risk
of developing an ICD, or is a consequence of it [1]. Rapid
eye movement sleep associated behavioral disorder (RBD),
which is common in PD patients, has also been associated
with male gender, as well as longer disease duration, and
medication doses [28]. While ICDs have recently been linked
to RBD [29], polysomnography studies have failed to
confirm an association between the two disorders, suggesting
that they do not have a common underlying pathophysiology
[30].
While the literature is divided on whether serum ferritin
levels are elevated in PD, results from the present cohort
indicated overall levels were higher in PD patients than
controls, but these results did not reach statistical
significance (p=.056), while serum iron and transferrin
saturation levels were comparable in the two groups. After
stratifying for gender serum ferritin levels were found to be
higher in males, both in the PD and control groups, as
previously reported [31-33].
There are few studies linking ferritin and impulsivity, and
the present study is the first to demonstrate an association
between ferritin levels and high impulsivity in PD patients.
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This was found to be gender-specific, in that it was present
only in males, and there was a progressive increase in ferritin
levels across the three impulsivity groups. Males in the high
impulsivity group, who also had the greatest degree of sleep
disturbance, had the highest ferritin levels (p<.05) as well as
increased transferrin saturation (p<.05) and raised serum iron
levels (p=.054), in keeping with a state of relative iron overload.
On the basis of the initial BIS-11 screening assessment we
identified a subset of male patients with high impulsivity
scores who fulfilled the diagnostic criteria for an ICD. This
subset consisted of 11 male patients who were diagnosed by
a clinical psychologist and appeared to present with a
somewhat greater disease severity (UPDRS III score), when
compared to the remaining male PD patient cohort. Unlike
previous studies, the ICD subset were not of early disease
onset or longer disease duration [3], with findings showing
age, disease duration and age of disease not being significant
variables of ICD prevalence in PD. Despite being of similar
age and disease duration, the ICD subset also displayed
significantly greater ferritin levels and transferrin saturation
when compared to the other male PD patients (p<.05), and
elevated transferrin saturation compared to healthy controls.
Moreover, consistent with the high impulsivity group, as
determined by BIS-11 scores, the ICD subset reported
significantly greater sleep disturbance than male PD patients
(p<.05). These results are somewhat surprising, as low brain
iron levels have been associated with increased sleep
disturbances and sleep fragmentation [34], a feature
documented in RLS [35]. However, it is known that patients
suffering from iron overload syndromes can also experience
similar sleep-related difficulties [36].

5. Limitations
Patient medication was optimised, and patient selection
was made on the basis of independence and mobility in that
those unable to walk unassisted were excluded, as
demonstrated by a comparatively low mean cohort Hoehn
and Yahr score. A number of limitations need to be
acknowledged. Firstly, while validated against standard
measures of sleep quality [26], interpretations of sleep
disturbance using self-reported questions from the MDSUPDRS should be considered with caution. Secondly,
following initial evaluation, not all patients with high
impulsivity scores volunteered to undergo a more detailed
follow-up consultation with a clinical psychologist and the
incidence of ICD may have been underestimated. As such, a
‘non-ICD’ patient subset could not be accurately determined,
and the manuscript acknowledges this limitation by
comparing the ICD group with the other male patients in the
cohort. Thirdly, although none of the PD patient cohort were
known to have any other condition that might be associated
with an elevated serum ferritin level, laboratory
investigations to exclude secondary causes of raised ferritin
levels were not carried out. Lastly, in view of the multiple
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factors which could contribute to a high impulsivity score in
a chronic disease such as PD, including premorbid
personality traits and subsequent effects of the disease itself
and medications, and in view of the cross-sectional nature of
this study, caution needs to be exercised in equating high
impulsivity levels as demonstrated by the BIS-11 screening
tool with the development of an ICD. Nevertheless, it is
noteworthy that all of the male patients with the highest
impulsivity scores were in fact found to fulfill the criteria for
an ICD on further evaluation.

6. Conclusions
In conclusion, using the BIS-11 screening tool, this study
demonstrated that male PD patients with the highest
impulsivity levels had significantly higher serum ferritin
levels and transferrin saturation, and also experienced the
most severe sleep disturbance. These associations were also
present in a subset of males who met the DSM-5 criteria for
an ICD. Although the findings do not necessarily imply a
causal relationship between high ferritin levels and high
levels of impulsivity and ICDs they suggest that there may be
a link between altered iron homeostasis and the development
of these disorders in males with PD, which warrants further
investigation. These findings also indicate the value of the
BIS-11 scale as a screening tool to identify patients who may
have an ICD who require further evaluation and treatment.
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